This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Neurostimulation Industry

3. TRENDS AND ISSUES II-8

Chip Makers Struggle to Meet Quality Demand II-8

Market Growth Attracts New Investors II-8

Neurostimulation on a Rise with Growing Indications II-8

Neurostimulation Market Marked by High Entry Barriers II-8

Increasing Acceptance of Neurostimulation due to Advanced

Clinical Benefits II-9

Powering Neurostimulation Devices-The Key to Success II-9

Market Development Initiatives to Fuel Market Growth II-9

Exploring Market Opportunities - The Technology Way II-10

Neurostimulation Devices - Growing Awareness and Acceptance

Among Physicians II-10

Synergy with Pharma & Biotech Companies Creates New Avenues II-10

Third-Party Reimbursement - A Vital Role to Play II-11

4. COMPETITIVE SCENARIO II-12Few Players Dominate Neurostimulation Market II-12Worldwide Neurostimulation Market: Leading Players byProduct Segment II-12Table 2: Leading Players in the Global NeurostimulationMarket (2011): Percentage Share Breakdown of Value Sales forMedtronic, St. Jude Medical, Boston Scientific, Cyberonicsand Others (includes corresponding Graph/Chart) II-13

Table 3: World Neurostimulation Market (2012): Percentage

Share Breakdown of Value Sales for Pain, Deafness, Epilepsy,

Movement Disorders, Depression, Stroke, Incontinence,

Gastroparesis and Obesity (includes corresponding

Graph/Chart) II-13

Product Offerings of Leading Players in the Neurostimulation

Market II-14

Select Spinal Cord Stimulation Product Offerings of St. Jude

and Medtronic II-14

Stimulation Parameters of Select SCS Products II-15

Companies Researching Neurostimulator Applications by

Indication II-15

5. EMERGING THERAPIES IN NEURO STIMULATION II-16ElectroCore to Demonstrate GammaCore at EHMTIC 2012 II-16University of Alabama Develops DBS Therapy for Parkinson'sDisease II-16California Based Medical Center Innovates Brain-controlledProsthetic Limb II-16Toronto Western Hospital Develops DBS Therapy for AlzheimersDisease II-17SPR Therapeutics Successfully Demonstrates PNS Therapy inStroke Victim II-17

6. NEUROMODULATION INDUSTRY: AN INSIGHT II-18

Attacking the Source of Pain - The Logic behind Neuromodulation II-18

Growth Prospects for Neuromodulation Industry II-18

7. PRODUCT OVERVIEW II-20Introduction to Neurostimulator II-20A Historical Note II-20Neurostimulation Devices by Product Segment II-20Spinal Cord Stimulation (SCS) II-21SCS - What it Treats II-22Segmentation by Type of Power Source II-22Implantable Pulse Generator Systems (IPGs) II-22Radio Frequency (RF) Systems II-22Market Assessment for RF Systems II-23Sacral Nerve Stimulation (SNS) II-23Deep Brain Stimulation (DBS) II-24Vagus Nerve Stimulation (VNS) II-24Gastric Electric Stimulation (GES) II-25Stimulation Device - How it Works II-25Neurostimulation & its Benefits II-25Prospective Application Areas for Neurostimulators - SelectIndications II-26Neurostimulation Indications and Use of Related Devices/Techniques in the US II-27Approved Indications for Spinal Cord Stimulation by GeographicRegions II-27Neurostimulation Devices - Technology & Safety Issues II-27

2 of 11

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs